Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases

Mesenchymal stem cells (MSC) secrete neuroprotective molecules that may be useful as an alternative to cell transplantation itself. Our purpose was to develop different pharmaceutical compositions based on conditioned medium (CM) of adipose MSC (aMSC) stimulated by and/or combined with nicotinamide...

Full description

Bibliographic Details
Main Authors: Maria L. Alonso-Alonso, Girish K. Srivastava, Ricardo Usategui-Martín, Maria T. García-Gutierrez, José Carlos Pastor, Ivan Fernandez-Bueno
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Stem Cells International
Online Access:http://dx.doi.org/10.1155/2020/9463548
id doaj-ecb2787c287c403bbfe4d003f09a31a6
record_format Article
spelling doaj-ecb2787c287c403bbfe4d003f09a31a62020-11-25T03:36:22ZengHindawi LimitedStem Cells International1687-966X1687-96782020-01-01202010.1155/2020/94635489463548Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative DiseasesMaria L. Alonso-Alonso0Girish K. Srivastava1Ricardo Usategui-Martín2Maria T. García-Gutierrez3José Carlos Pastor4Ivan Fernandez-Bueno5Instituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainInstituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainInstituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainInstituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainInstituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainInstituto Universitario de Oftalmobiología Aplicada (IOBA), Retina Group, Universidad de Valladolid, Valladolid 47011, SpainMesenchymal stem cells (MSC) secrete neuroprotective molecules that may be useful as an alternative to cell transplantation itself. Our purpose was to develop different pharmaceutical compositions based on conditioned medium (CM) of adipose MSC (aMSC) stimulated by and/or combined with nicotinamide (NIC), vasoactive intestinal peptide (VIP), or both factors; and to evaluate in vitro their proliferative and neuroprotective potential. Nine pharmaceutical compositions were developed from 3 experimental approaches: (1) unstimulated aMSC-CM collected and combined with NIC, VIP, or both factors (NIC+VIP), referred to as the aMSC-CM combined composition; (2) aMSC-CM collected just after stimulation with the mentioned factors and containing them, referred to as the aMSC-CM stimulated-combined composition; and (3) aMSC-CM previously stimulated with the factors, referred to as the aMSC stimulated composition. The potential of the pharmaceutical compositions to increase cell proliferation under oxidative stress and neuroprotection were evaluated in vitro by using a subacute oxidative stress model of retinal pigment epithelium cells (line ARPE-19) and spontaneous degenerative neuroretina model. Results showed that oxidatively stressed ARPE-19 cells exposed to aMSC-CM stimulated and stimulated-combined with NIC or NIC+VIP tended to have better recovery from the oxidative stress status. Neuroretinal explants cultured with aMSC-CM stimulated-combined with NIC+VIP had better preservation of the neuroretinal morphology, mainly photoreceptors, and a lower degree of glial cell activation. In conclusion, aMSC-CM stimulated-combined with NIC+VIP contributed to improving the proliferative and neuroprotective properties of the aMSC secretome. Further studies are necessary to evaluate higher concentrations of the drugs and to characterize specifically the aMSC-secreted factors related to neuroprotection. However, this study supports the possibility of improving the potential of new effective pharmaceutical compositions based on the secretome of MSC plus exogenous factors or drugs without the need to inject cells into the eye, which can be very useful in retinal pathologies.http://dx.doi.org/10.1155/2020/9463548
collection DOAJ
language English
format Article
sources DOAJ
author Maria L. Alonso-Alonso
Girish K. Srivastava
Ricardo Usategui-Martín
Maria T. García-Gutierrez
José Carlos Pastor
Ivan Fernandez-Bueno
spellingShingle Maria L. Alonso-Alonso
Girish K. Srivastava
Ricardo Usategui-Martín
Maria T. García-Gutierrez
José Carlos Pastor
Ivan Fernandez-Bueno
Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
Stem Cells International
author_facet Maria L. Alonso-Alonso
Girish K. Srivastava
Ricardo Usategui-Martín
Maria T. García-Gutierrez
José Carlos Pastor
Ivan Fernandez-Bueno
author_sort Maria L. Alonso-Alonso
title Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
title_short Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
title_full Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
title_fullStr Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
title_full_unstemmed Mesenchymal Stem Cell Secretome Enhancement by Nicotinamide and Vasoactive Intestinal Peptide: A New Therapeutic Approach for Retinal Degenerative Diseases
title_sort mesenchymal stem cell secretome enhancement by nicotinamide and vasoactive intestinal peptide: a new therapeutic approach for retinal degenerative diseases
publisher Hindawi Limited
series Stem Cells International
issn 1687-966X
1687-9678
publishDate 2020-01-01
description Mesenchymal stem cells (MSC) secrete neuroprotective molecules that may be useful as an alternative to cell transplantation itself. Our purpose was to develop different pharmaceutical compositions based on conditioned medium (CM) of adipose MSC (aMSC) stimulated by and/or combined with nicotinamide (NIC), vasoactive intestinal peptide (VIP), or both factors; and to evaluate in vitro their proliferative and neuroprotective potential. Nine pharmaceutical compositions were developed from 3 experimental approaches: (1) unstimulated aMSC-CM collected and combined with NIC, VIP, or both factors (NIC+VIP), referred to as the aMSC-CM combined composition; (2) aMSC-CM collected just after stimulation with the mentioned factors and containing them, referred to as the aMSC-CM stimulated-combined composition; and (3) aMSC-CM previously stimulated with the factors, referred to as the aMSC stimulated composition. The potential of the pharmaceutical compositions to increase cell proliferation under oxidative stress and neuroprotection were evaluated in vitro by using a subacute oxidative stress model of retinal pigment epithelium cells (line ARPE-19) and spontaneous degenerative neuroretina model. Results showed that oxidatively stressed ARPE-19 cells exposed to aMSC-CM stimulated and stimulated-combined with NIC or NIC+VIP tended to have better recovery from the oxidative stress status. Neuroretinal explants cultured with aMSC-CM stimulated-combined with NIC+VIP had better preservation of the neuroretinal morphology, mainly photoreceptors, and a lower degree of glial cell activation. In conclusion, aMSC-CM stimulated-combined with NIC+VIP contributed to improving the proliferative and neuroprotective properties of the aMSC secretome. Further studies are necessary to evaluate higher concentrations of the drugs and to characterize specifically the aMSC-secreted factors related to neuroprotection. However, this study supports the possibility of improving the potential of new effective pharmaceutical compositions based on the secretome of MSC plus exogenous factors or drugs without the need to inject cells into the eye, which can be very useful in retinal pathologies.
url http://dx.doi.org/10.1155/2020/9463548
work_keys_str_mv AT marialalonsoalonso mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
AT girishksrivastava mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
AT ricardousateguimartin mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
AT mariatgarciagutierrez mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
AT josecarlospastor mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
AT ivanfernandezbueno mesenchymalstemcellsecretomeenhancementbynicotinamideandvasoactiveintestinalpeptideanewtherapeuticapproachforretinaldegenerativediseases
_version_ 1715167198075420672